Hotspur Technologies Commences US Launch at Veith/AIM Conference in New York City
NEW YORK, Nov. 16, 2011 /PRNewswire/ — Hotspur Technologies today announced the launch of the company’s GPSCath(TM) Balloon Dilatation Catheter in the United States and select international markets. The company made the announcement today.
Hotspur’s innovative GPSCath(TM) Balloon Dilatation Catheter integrates a proprietary valve into a balloon catheter, allowing physicians to inject contrast during a procedure without the need for removal of the balloon catheter or adjustment of guidewire position. Combining these multiple functions into one device can potentially reduce the time and expense required to complete peripheral angioplasty procedures, allowing physicians to work more efficiently.
To support this initial launch, Hotspur has entered into exclusive distribution agreements with SurgPro, LLC, and TD Medical, leading medical device distributors in the interventional radiology space for the southeastern United States and the Netherlands, respectively. While these regions are the initial focus of Hotspur’s launch, the company will continue to expand its distribution network throughout the United States and other select international markets in 2012.
“My use of the GPSCath(TM) has been a highly positive experience, and I look forward to using more of these devices in the future as well as seeing what other innovations Hotspur will bring to the market,” said Dr. Tom DiBartholomeo, an interventional radiologist and early adopter of the product.
During the company’s recently completed limited market launch, over 150 GPSCath(TM) balloon catheters were successfully used in more than 100 dialysis access procedures. This initial product experience validated the performance of both the angioplasty and injection functions of the GPSCath(TM), while also reinforcing the benefit of combining the multiple functions into one unique catheter.
“I am very excited about the launch of GPSCath(TM). We have been very impressed with the device performance, and we feel that the GPSCath(TM) will make a significant impact in providing better care for patients and reducing procedure times for physicians,” said Gwen Watanabe, President & CEO of Hotspur Technologies. “In the near future, I am also looking forward to launching a number of new novel products in the US market, which will underscore the strength of the company’s pipeline and the depth of our R&D.”
About Hotspur Technologies
Founded in 2008 and located in Mountain View, California, Hotspur Technologies (www.hotspur-inc.com) is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company’s products are based on a unique technology that opens blood vessels more efficiently and less invasively. The firm’s VisioValve(TM) technology serves as a launching point to improve patient outcome and physician efficiency. Hotspur is privately held. Its investors include ONSET Ventures, Finistere Ventures, BioStar Ventures, Saratoga Ventures, Millennium Life Sciences Ventures, Incept, and Versant Ventures.
CONTACT: Will Martin, (770) 639-2777, firstname.lastname@example.org
SOURCE Hotspur Technologies